Programmed death ligand 1 (PD-L1) antibody (atezolizumab): Immune checkpoint ligand PD-L1 has been found to increase in invasive lung fibroblasts and drives lung fibrosis in a humanized IPF model in mice. Here, CD274 is linked to idiopathic pulmonary fibrosis.